BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 20010622)

  • 21. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
    Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
    Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors.
    Ishii E; Eguchi H; Matsuzaki A; Koga H; Yanai F; Kuroda H; Kawakami K; Ayukawa H; Akiyoshi K; Kamizono J; Tamai Y; Kinukawa N; Okamura J
    Med Pediatr Oncol; 2001 Jul; 37(1):10-9. PubMed ID: 11466717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol.
    Toft N; Birgens H; Abrahamsson J; Bernell P; Griškevičius L; Hallböök H; Heyman M; Holm MS; Hulegårdh E; Klausen TW; Marquart HV; Jónsson OG; Nielsen OJ; Quist-Paulsen P; Taskinen M; Vaitkeviciene G; Vettenranta K; Åsberg A; Schmiegelow K
    Eur J Haematol; 2013 May; 90(5):404-12. PubMed ID: 23461707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
    Paolucci G; Vecchi V; Favre C; Miniero R; Madon E; Pession A; Rondelli R; De Rossi G; Lo Nigro L; Porta F; Santoro N; Indolfi P; Basso G; Conter V; Aricò M;
    Haematologica; 2001 May; 86(5):478-84. PubMed ID: 11410410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer.
    Levinsen M; Rotevatn EØ; Rosthøj S; Nersting J; Abrahamsson J; Appell ML; Bergan S; Bechensteen AG; Harila-Saari A; Heyman M; Jonsson OG; Maxild JB; Niemi M; Söderhäll S; Schmiegelow K;
    Pediatr Blood Cancer; 2014 May; 61(5):797-802. PubMed ID: 24395436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.
    Sancho JM; Ribera JM; Oriol A; Hernandez-Rivas JM; Rivas C; Bethencourt C; Parody R; Deben G; Bello JL; Feliu E;
    Cancer; 2006 Jun; 106(12):2540-6. PubMed ID: 16700036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
    Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
    Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
    Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
    Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
    Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
    Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
    Yeoh AE; Ariffin H; Chai EL; Kwok CS; Chan YH; Ponnudurai K; Campana D; Tan PL; Chan MY; Kham SK; Chong LA; Tan AM; Lin HP; Quah TC
    J Clin Oncol; 2012 Jul; 30(19):2384-92. PubMed ID: 22614971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group.
    Crist W; Shuster J; Look T; Borowitz M; Behm F; Bowman P; Frankel L; Pullen J; Krance R; Steuber P
    Leukemia; 1992; 6 Suppl 2():162-6. PubMed ID: 1578922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
    Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
    Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol.
    Gandemer V; Pochon C; Oger E; Dalle JH; Michel G; Schmitt C; de Berranger E; Galambrun C; Cavé H; Cayuela JM; Grardel N; Macintyre E; Margueritte G; Méchinaud F; Rorhlich P; Lutz P; Demeocq F; Schneider P; Plantaz D; Poirée M; Bordigoni P
    Br J Haematol; 2014 May; 165(3):392-401. PubMed ID: 24479958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of acute lymphoblastic leukemia in adults with seven-drug induction therapy and intensive consolidation with or without autologous stem cell transplantation followed by maintenance therapy. Experience of a single center].
    Doubek M; Mayer J; Korístek Z; Protivánková M; Brychtová Y; Oborilová A; Král Z; Klabusay M; Tomíska M; Buchtová I; Vorlícek J
    Cas Lek Cesk; 2002 Mar; 141(4):122-6. PubMed ID: 12046256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The utility of performing the initial lumbar puncture on day 8 in remission induction therapy for childhood acute lymphoblastic leukemia: TCCSG L99-15 study.
    Hasegawa D; Manabe A; Ohara A; Kikuchi A; Koh K; Kiyokawa N; Fukushima T; Ishida Y; Saito T; Hanada R; Tsuchida M;
    Pediatr Blood Cancer; 2012 Jan; 58(1):23-30. PubMed ID: 21254378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term results of the Japanese Childhood Cancer and Leukemia Study Group studies 811, 841, 874 and 911 on childhood acute lymphoblastic leukemia.
    Tsurusawa M; Shimomura Y; Asami K; Kikuta A; Watanabe A; Horikoshi Y; Matsushita T; Kanegane H; Ohta S; Iwai A; Mugishima H; Koizumi S;
    Leukemia; 2010 Feb; 24(2):335-44. PubMed ID: 20016539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of intensive post-remission chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia and lymphoblastic lymphoma: Japan Clinical Oncology Group Study, JCOG9402.
    Azuma T; Tobinai K; Takeyama K; Shibata T; Hidaka M; Kurosawa M; Kasai M; Chou T; Fukushima N; Mukai K; Tsukasaki K; Shimoyama M;
    Jpn J Clin Oncol; 2012 May; 42(5):394-404. PubMed ID: 22422899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of children with high-risk acute lymphoblastic leukemia (HR-ALL): Nordic results on an intensive regimen with restricted central nervous system irradiation.
    Saarinen-Pihkala UM; Gustafsson G; Carlsen N; Flaegstad T; Forestier E; Glomstein A; Kristinsson J; Lanning M; Schroeder H; Mellander L;
    Pediatr Blood Cancer; 2004 Jan; 42(1):8-23. PubMed ID: 14752789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.